Skip to main content

Avoro Capital Advisors LLC's Form 4 filing

Scribe Therapeutics, Inc.SCTX · filed Jul 28, 2026

Accession no.
0000902664-26-003270
Filed
Jul 28, 2026, 9:30 PM ET
Trade date
Jul 24-28, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market purchases total $36.3M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Avoro Capital Advisors LLCCIK 0001633313Director, 10% Owner, Other: See Remarks
Aghazadeh BehzadCIK 0001701815Director, 10% Owner, Other: See Remarks
Avoro Ventures LLCCIK 0001879253Director, Other: See Remarks

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 24, 2026Common Stock, par value $0.0001 per sharePPurchaseAcquired+2,333,333$15.00F1+$34,999,9953,030,983Indirect
Jul 24, 2026Common Stock, par value $0.0001 per sharePPurchaseAcquired+50,000$22.31F2+$1,115,5003,080,983Indirect
Jul 28, 2026Common Stock, par value $0.0001 per sharePPurchaseAcquired+7,905$18.25F2+$144,266.253,088,888Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds").

Referenced by the price of 1 transaction in Table I.

F2

The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.

Referenced by the price of 2 transactions in Table I.

Remarks

Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.

Read the full filing on SEC EDGAR (opens in a new tab)